Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway

BACKGROUND: Cyclin-dependent kinase 9 (CDK9) is a promising prognostic marker and therapeutic target in cancers. Bufalin is an effective anti-tumour agent; however, the clinical application of bufalin is limited due to its high toxicity. Acetyl-bufalin, the bufalin prodrug, was designed and synthesi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Cancer
Asıl Yazarlar: Yang, Lehe, Zhou, Feng, Zhuang, Yan, Liu, Yanan, Xu, Lingyuan, Zhao, Haiyang, Xiang, Youqun, Dai, Xuanxuan, Liu, Zhiguo, Huang, Xiaoying, Wang, Liangxing, Zhao, Chengguang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7851395/
https://ncbi.nlm.nih.gov/pubmed/33122847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01135-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller